Sep 20, 2021 / 06:05PM GMT
Shaymus Contorno - Oppenheimer & Co. - Analyst
Good afternoon. I am Shaymus Contorno from Oppenheimer's MedTech research team. Next up at our Fall Medtech Summit, we are pleased to welcome Barton Bandy, CEO; and Tom Stankovich, CFO, from ReShape Lifesciences.
With that, I'll turn it over to you, Bart and Tom.
Bart Bandy - ReShape Lifesciences Inc. - President and CEO
Great. Thank you, Shaymus. Welcome, everyone. It's our pleasure to present an update on ReShape Lifesciences. A lot has happened to our Company over the past few months. And we are really moving fast forward on some of the different projects that we've built out over the pandemic to make sure that we were ready, poised, and able to execute once we completed our merger with Obalon and brought in the funding necessary for our strategy and our execution. So as we go through that, we have our Safe Harbor statement and risk factors stated at the beginning of the presentation. I will give everybody a few seconds to review this.
And then we'll talk about it from an executive summary
ReShape Lifesciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers